June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell
Cotellic/Tecentriq combo misses in melanoma
Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab in the Phase III IMspire170 trial for first-line BRAF V600 wild-type advanced melanoma. Cotellic is a MEK inhibitor, and Tecentriq is an anti-PD-L1 mAb.
Progenics planning neuroendocrine tumor basket trial
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) plans to start a basket trial by year end of Azedra iobenguane I 131 to treat iobenguane scan-positive unresectable or metastatic neuroendocrine tumors (NETs), which can form in a variety of tissues. Progenics is seeking to expand the label of the radiolabeled norepinephrine analog, which is approved for iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. ...